The minimal residue disease testing market size is projected to surge from US$ 3.55 billion in 2023 to US$ 8.94 billion by 2031; the market is estimated to record a CAGR of 12.24% during 2023–2031.
The Minimal Residue Disease (MRD) Testing Market is expanding due to increasing demand for precise cancer diagnostics and monitoring. MRD testing aids in detecting residual cancer cells post-treatment, driving its adoption in personalized medicine. Technological advancements in genomic and molecular diagnostics, coupled with rising prevalence of hematologic cancers, fuel market growth. Key players focus on innovation and regulatory approvals to enhance adoption.
Source: The Insight Partners
Canadian pharmacies not requiring prescription
Caramelized Australian Balsamic: Craving Perfection? Aussie Basket Delivers Every Time
6G Market Upcoming Opportunities, Trends and Industry Outlook 2025
3D Printing Services in Coimbatore: Choose WOL3D Coimbatore for Superior Quality
Indulge in Mutual Massage in London for Connection and Complete Relaxation
